Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QRxPharma Pty Ltd.

This article was originally published in Start Up

Executive Summary

QRx's lead (Phase II) candidate is a morphine/oxycodone combination that takes advantage of the synergistic effect of those two opioids when combined to produce a more potent painkiller, with fewer side effects, than morphine administered alone. The company is also developing an extended-release version of the drug and has a platform for discovering venom-based therapeutics.

You may also be interested in...



Pain Therapeutics: A Market Rich in Unmet Medical Need and Competition

Start-ups venturing into the pain management arena will find them selves in a therapeutic category rich in both unmet medical need and competition. To compete, a number of newer companies are pursuing business models that balance the risks inherent in developing novel painkillers with more reliable, predictable routes to commercialization--such as creating next-generation versions of off-patent drugs and inlicensed technology, as well as establishing IP around already-elucidated targets.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel